How do I buy Novartis (NVS) stock?

Buying Novartis (NVS) stock is now easy and instant through the Gotrade app. Download the Gotrade app from the App Store or Google Play. Create an account and complete KYC. Make a deposit. Search for the code "NVS", then tap "Trade". Tap the "Buy" button. Enter the amount you want to buy. You have two options: Buy NVS by number of shares. Buy fractional shares in dollars, starting from $1. Swipe up to confirm your order, and you're done!

How do I tell if NVS is expensive or cheap?

There's no single perfect answer, but common approaches include: Compare valuation (e.g., P/E, P/S) against historical averages or competitors. Review revenue and earnings growth. Check margins and cash flow. Evaluate business outlook and the company's position within its industry. You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Novartis (NVS) Stock

Q: What is the minimum investment for NVS on Gotrade?

On Gotrade , you don't have to buy a full lot. With fractional shares, you can start investing in Novartis from just $1. A small budget shouldn't stop you from building a US stock portfolio.

NEW YORK STOCK EXCHANGE, INC. · NVS

Trade NVS

Key stats

Market cap: $311.59B
Price / Earnings ratio: 30.1x
EPS (TTM): $5.25
Volume: Loading
52-week high: $170.46
52-week low: $123.24
EPS vs analyst estimate: -1.7%Q3 FY25 · $2.25 vs $2.29

Source: third-party data provider, as of November 5, 2026

EPS estimate: analyst consensus

Compare with NVS

Technical indicators

RSI 14: 70.50
MACD 12/26/9: 4.28
EMA 9 of MACD: 3.14
MACD histogram: 1.14
SMA 50: $148.58; Price above SMA 50
EMA 50: $151.24; Price above EMA 50
SMA 200: $152.08; Price above SMA 200
EMA 200: $148.71; Price above EMA 200

Calculated by Gotrade from daily closing prices, as of November 4, 2026. Technical data, not a recommendation.

Analyst ratings

Analyst consensus: Sell

Based on 2 analyst ratings

Strong Sell1

Sell0

Hold1

Buy0

Strong Buy0

Third-party analyst opinion, not a recommendation from Gotrade.

Financials

Performance

Revenue

Net income

Net margin %

2025

68B45B22B0

Debt & Balance Sheet

Total assets

Total liabilities

2025

133B88B44B0

Revenue to Profit

2025

$56.7B

Revenue

$0.0

Cost of revenue

$43.0B

Gross profit

$0.0

Operating expenses

$14.0B

Net income

Earnings

EPS forecast

Actual EPS

$2.25

$2.29

Q3FY25

$1.94

Q4FY25

$2.26

Q1FY26

$2.49

Q2FY26

$2.27

Q3FY26

The market is expecting earnings per share of $2.27 for this quarter. The company has not yet shared when it is announcing earnings.

Source: third-party data provider

About Novartis

Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development.

SectorHealthcare

IndustryDrug Manufacturers - General

Employees75,267

CEODr. Vasant Narasimhan M.D.

IPO DateNov 18, 1991

HeadquartersBasel, Switzerland

Key Executives

Name	Title	Year Born
Dr. Vasant Narasimhan M.D.	Chief Executive Officer	1976
Mr. Mukul Mehta	Chief Financial Officer	1973
Mr. Victor Bulto	President of US	1978
Dr. Patrick Horber M.D.	President of International	1970
Dr. Steffen Lang Ph.D.	President of Operations	1967
Paul Penepent	Head of Group Financial Reporting and Accounting	—
Ms. Sloan Simpson	Global Head of Investor Relations	—
Ms. Karen L. Hale	Chief Legal & Compliance Officer	1968
Dr. Robert Kowalski Pharm.D.	Chief People & Organization Officer	1968
Mr. Evan Beckman	Global Head of Translational Medicine at Novartis Institute for BioMedical Research	—

Seasonality

Monthly price change (%)

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2021											-4.2	+9.6
2022	-1.1	-0.8	+0.7	+0.4	+3.8	-5.7	+1.7	-6.0	-5.4	+5.8	+10.5	+1.0
2023	-1.7	-4.7	+9.8	+10.9	-6.1	+3.9	+6.2	-2.7	+1.1	-7.8	+3.9	+2.9
2024	+2.4	-4.1	-5.2	+1.3	+5.8	+3.6	+4.6	+7.8	-2.9	-5.4	-3.3	-7.1
2025	+7.8	+3.4	+0.8	+3.5	+4.0	+3.7	-7.6	+9.8	+1.3	-6.0	+5.3	+6.9
2026	+7.3	+11.6	-8.5	-4.7	+2.5	+7.6	+1.3	-1.0	-11.6	+14.0	+2.1

Stocks in the same sector

FAQ

Buying Novartis (NVS) stock is now easy and instant through the Gotrade app.

Download the Gotrade app from the App Store or Google Play.
Create an account and complete KYC.
Make a deposit.
Search for the code "NVS", then tap "Trade".
Tap the "Buy" button.
Enter the amount you want to buy. You have two options:
1. Buy NVS by number of shares.
2. Buy fractional shares in dollars, starting from $1.
Swipe up to confirm your order, and you're done!

On Gotrade, you don't have to buy a full lot. With fractional shares, you can start investing in Novartis from just $1. A small budget shouldn't stop you from building a US stock portfolio.

Yes, Novartis regularly pays dividends to shareholders. Currently, the estimated dividend yield for NVS is around 1.88% per year. On Gotrade, cash dividends will be automatically credited to your account balance (after taxes).

Gotrade is the trading name of Gotrade Securities Inc., which is registered with and supervised by the Labuan Financial Services Authority (LFSA).

You can place orders 24/7. Transactions will be executed when the US market (NYSE/NASDAQ) is open, from 9:30 PM to 4:00 AM WIB, or 8:30 PM to 3:00 AM WIB during Daylight Saving Time. Gotrade also provides access to pre-market and after-hours trading, so you have more flexibility and aren't limited to regular working hours.

Market hours may change due to daylight saving time and holidays. In Gotrade, you can see the market status (open/closed) directly in the app.

There's no single perfect answer, but common approaches include:

Compare valuation (e.g., P/E, P/S) against historical averages or competitors.
Review revenue and earnings growth.
Check margins and cash flow.
Evaluate business outlook and the company's position within its industry.

You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Trade Faster. Easier. Smarter.

#ReadyGoTrade

Welcome Reward up to $1,888

Create an account and trade US stocks on Gotrade

Download app

*Terms & conditions apply

Novartis (NVS) Stock

Key stats

Compare with NVS

Recent news

SLS Stock Snaps 4-Day Slide As Retail Eyes ASH Abstracts — Fresh Filings Reveal Bigger Swiss, Arizona Pension Bets

SLS Stock Snaps 4-Day Slide As Retail Eyes ASH Abstracts — Fresh Filings Reveal Bigger Swiss, Arizona Pension Bets

Novartis: 3 Key Takeaways for Long-Term Investors

Novartis: 3 Key Takeaways for Long-Term Investors

3 Stocks to Watch Following Guidance Upgrades

3 Stocks to Watch Following Guidance Upgrades

Novartis heart drug failure leaves doctors seeking evidence for genetic cholesterol target

Novartis heart drug failure leaves doctors seeking evidence for genetic cholesterol target

Technical indicators

Analyst ratings

Financials

Performance

Debt & Balance Sheet

Revenue to Profit

Earnings

Latest news

SLS Stock Snaps 4-Day Slide As Retail Eyes ASH Abstracts — Fresh Filings Reveal Bigger Swiss, Arizona Pension Bets

SLS Stock Snaps 4-Day Slide As Retail Eyes ASH Abstracts — Fresh Filings Reveal Bigger Swiss, Arizona Pension Bets

Novartis: 3 Key Takeaways for Long-Term Investors

Novartis: 3 Key Takeaways for Long-Term Investors

3 Stocks to Watch Following Guidance Upgrades

3 Stocks to Watch Following Guidance Upgrades

Novartis heart drug failure leaves doctors seeking evidence for genetic cholesterol target

Novartis heart drug failure leaves doctors seeking evidence for genetic cholesterol target

Companies promised AI gains— here's how the payoff showed up in earnings

Companies promised AI gains— here's how the payoff showed up in earnings

All You Need to Know About Novartis (NVS) Rating Upgrade to Buy

All You Need to Know About Novartis (NVS) Rating Upgrade to Buy

Why Novartis (NVS) is a Top Momentum Stock for the Long-Term

Why Novartis (NVS) is a Top Momentum Stock for the Long-Term

A pharma giant is moving past one patent cliff — but another is already looming

A pharma giant is moving past one patent cliff — but another is already looming

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

What Novartis (NVS) Said on Its Q3 Earnings Call

What Novartis (NVS) Said on Its Q3 Earnings Call

About Novartis

Key Executives

Fundamentals

Valuation

Profitability

Trading

Dividend

Technical indicators

Analyst views

Seasonality

Corporate actions

Upcoming

Past

Compare stocks

Market cap

Price / Earnings ratio

Price / Sales ratio

Dividend yield

Average volume

Earnings per share

Stocks in the same sector

FAQ

Trade Faster. Easier. Smarter.

#ReadyGoTrade